Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 16 studies | 27% ± 7% | |
lung | 15 studies | 25% ± 5% | |
intestine | 5 studies | 19% ± 6% | |
liver | 5 studies | 20% ± 6% | |
brain | 4 studies | 26% ± 6% | |
bone marrow | 3 studies | 24% ± 5% | |
eye | 3 studies | 18% ± 1% | |
lymph node | 3 studies | 24% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 10045.59 | 578 / 578 | 100% | 64.73 | 1155 / 1155 |
ovary | 100% | 8022.48 | 180 / 180 | 100% | 40.72 | 430 / 430 |
prostate | 100% | 3403.75 | 245 / 245 | 100% | 39.51 | 502 / 502 |
stomach | 100% | 3663.39 | 359 / 359 | 100% | 39.04 | 286 / 286 |
uterus | 100% | 4888.34 | 170 / 170 | 100% | 47.42 | 459 / 459 |
esophagus | 100% | 6021.07 | 1444 / 1445 | 100% | 37.89 | 183 / 183 |
thymus | 100% | 4107.26 | 653 / 653 | 100% | 53.80 | 604 / 605 |
breast | 100% | 3665.67 | 459 / 459 | 100% | 42.30 | 1116 / 1118 |
intestine | 100% | 4244.36 | 966 / 966 | 100% | 42.40 | 526 / 527 |
bladder | 100% | 4059.62 | 21 / 21 | 100% | 45.51 | 503 / 504 |
kidney | 100% | 3255.93 | 89 / 89 | 100% | 42.96 | 898 / 901 |
skin | 100% | 4283.26 | 1806 / 1809 | 99% | 31.75 | 469 / 472 |
adrenal gland | 100% | 6168.95 | 258 / 258 | 99% | 29.21 | 227 / 230 |
pancreas | 98% | 3131.73 | 322 / 328 | 100% | 36.97 | 178 / 178 |
brain | 96% | 2143.98 | 2536 / 2642 | 100% | 26.18 | 705 / 705 |
liver | 95% | 1431.67 | 215 / 226 | 98% | 20.92 | 399 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 32.39 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 92.97 | 29 / 29 |
spleen | 100% | 6242.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 47.58 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.74 | 1 / 1 |
blood vessel | 100% | 4299.71 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 3683.91 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 12654.94 | 928 / 929 | 0% | 0 | 0 / 0 |
muscle | 100% | 2482.43 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 2232.05 | 830 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043434 | Biological process | response to peptide hormone |
GO_0019370 | Biological process | leukotriene biosynthetic process |
GO_0060509 | Biological process | type I pneumocyte differentiation |
GO_0006508 | Biological process | proteolysis |
GO_0010043 | Biological process | response to zinc ion |
GO_0019538 | Biological process | protein metabolic process |
GO_0006629 | Biological process | lipid metabolic process |
GO_0043171 | Biological process | peptide catabolic process |
GO_0005576 | Cellular component | extracellular region |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_1904724 | Cellular component | tertiary granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0008233 | Molecular function | peptidase activity |
GO_0070006 | Molecular function | metalloaminopeptidase activity |
GO_0045148 | Molecular function | tripeptide aminopeptidase activity |
GO_0004301 | Molecular function | epoxide hydrolase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004177 | Molecular function | aminopeptidase activity |
GO_0003723 | Molecular function | RNA binding |
GO_0004463 | Molecular function | leukotriene-A4 hydrolase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | LTA4H |
Protein name | Leukotriene A4 hydrolase (cDNA FLJ51712, moderately similar to Leukotriene A-4 hydrolase) LTA4H protein Leukotriene A-4 hydrolase (LTA-4 hydrolase) (EC 3.3.2.6) (Leukotriene A(4) hydrolase) (Tripeptide aminopeptidase LTA4H) (EC 3.4.11.4) |
Synonyms | LTA4 |
Description | FUNCTION: Bifunctional zinc metalloenzyme that comprises both epoxide hydrolase (EH) and aminopeptidase activities. Acts as an epoxide hydrolase to catalyze the conversion of LTA4 to the pro-inflammatory mediator leukotriene B4 (LTB4) . Has also aminopeptidase activity, with high affinity for N-terminal arginines of various synthetic tripeptides . In addition to its pro-inflammatory EH activity, may also counteract inflammation by its aminopeptidase activity, which inactivates by cleavage another neutrophil attractant, the tripeptide Pro-Gly-Pro (PGP), a bioactive fragment of collagen generated by the action of matrix metalloproteinase-9 (MMP9) and prolylendopeptidase (PREPL) . Involved also in the biosynthesis of resolvin E1 and 18S-resolvin E1 from eicosapentaenoic acid, two lipid mediators that show potent anti-inflammatory and pro-resolving actions . . |
Accessions | ENST00000552789.5 [P09960-4] ENST00000548852.5 ENST00000413268.6 [P09960-3] Q49AK0 B4DEH5 ENST00000228740.7 [P09960-1] P09960 |